Snowball logo
logo
TECH_logo

Bio-Techne Corporation

TECH β€’ NASDAQ
$72.17-$0.06Β  (0.08%)
TECH's revenue has shown a consistent upward traje...
View AAPL example
Estimate
P/E
103.1
EPS
0.7
Beta
1.277
Growth
Revenue, YoY
-1.51%
Net income, YoY
126.04%
FCF, YoY
150.27%
Forecast
P/E (FWD)
35.3
EPS (FWD)
2.043
Dividends
Div. yield, TTM
1.34%
Annual payout, TTM
$0.97
Next ex. div date
August 17, 26
Payout
45.47%
Div.rating
About the company
Ticker
TECH
ISIN
US09073M1045
Country
United States of America
Sector (GICS)
Healthcare
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Frequently asked questions

What sector does Bio-Techne Corporation (TECH) operate in?

Bio-Techne Corporation belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Bio-Techne Corporation (TECH) current stock price?

As of the latest data, Bio-Techne Corporation stock price is $72.17, with a previous close of $72.23. Bio-Techne Corporation lost -$0.06 in the last trading session, representing a -0.08% loss.

What is Bio-Techne Corporation (TECH) current market capitalization?

Bio-Techne Corporation market cap is approximately 11.24 billion.

What is Bio-Techne Corporation (TECH) Earnings Per Share (EPS)?

The trailing EPS is $0.70, and the forward EPS is $2.04.

What is Bio-Techne Corporation (TECH) Price-to-Earnings (P/E) ratio?

Bio-Techne Corporation current P/E ratio is 103.1, with a forward P/E of 35.32.

What is Bio-Techne Corporation (TECH) EBITDA?

Bio-Techne Corporation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 98.62 million.

Does Bio-Techne Corporation (TECH) pay dividends?

Yes. Bio-Techne Corporation pays quarterly dividends with an annualized yield of 1.34% and an estimated annual payout of $0.97 per share.

When is the next ex-dividend date for Bio-Techne Corporation (TECH)?

The next ex-dividend date is scheduled for August 17, 2026.

How did Bio-Techne Corporation (TECH) perform in its most recent earnings report?

In the last report (June 30, 2026), Bio-Techne Corporation posted an EPS surprise of 0% and a revenue surprise of -1.47%.

What is Bio-Techne Corporation (TECH) beta (volatility) score?

Bio-Techne Corporation has a beta of 1.277, suggesting it is more volatile than the market.